British pharma company GlaxoSmithKline (GSK) plans to invest up to $800 million to expand drug substance and drug product manufacturing capabilities at the company’s US site in Marietta, Pennsylvania. The investment, which GSK said is its largest ever in US manufacturing, is expected to create more than 200 new jobs.
An innovative manufacturing platform called integrated continuous manufacturing (ICM) represents a completely modernized model for drug manufacturing. In contrast to batch processes, ICM’s unique operational advantages will allow for cost-competitive end-to-end manufacturing and enable a more robust and responsive supply chain for critical drugs.
Bristol Myers Squibb (BMS) wants to invest $400 million for the construction and design of a sterile drug product (SDP) facility at its Cruiserath campus in Dublin, Ireland, significantly expanding manufacturing and laboratory capacity at the site.
Portuguese CDMO Hovione has expanded its continuous manufacturing capabilities with the start-up of a new facility at Loures. The company said it can now offer customers a commercial continuous tableting platform to support their key needs.
Chinese contract research, development and manufacturing organization WuXi STA, a subsidiary of WuXi AppTec, has broken ground on a new pharmaceutical campus in Middletown, Delaware, USA.
